Jazz Pharmaceuticals plc — Director's Dealing 2018

Feb 28, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2018-02-26

Reporting Person: Young Matthew P. (EVP & CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-02-26	Ordinary Shares	F	2253	$147.44	Disposed	36706	Direct
2018-02-27	Ordinary Shares	S	1016	$144.961	Disposed	35690	Direct
2018-02-27	Ordinary Shares	S	600	$145.8333	Disposed	35090	Direct
2018-02-27	Ordinary Shares	S	300	$147.2967	Disposed	34790	Direct
2018-02-27	Ordinary Shares	F	606	$143.8	Disposed	34184	Direct
2018-02-28	Ordinary Shares	S	200	$145.245	Disposed	33984	Direct
2018-02-28	Ordinary Shares	S	119	$147.5561	Disposed	33865	Direct
2018-02-28	Ordinary Shares	S	200	$149.015	Disposed	33665	Direct
2018-02-28	Ordinary Shares	S	700	$150.0	Disposed	32965	Direct

Footnotes

F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.

F2: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F3: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $144.3100 to $145.2600. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F4: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $145.4300 to $146.2700. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F5: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $147.0600 to $147.4400. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F6: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $145.0500 to $145.4400. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F7: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $147.2200 to $147.6200. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F8: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $148.6200 to $149.4100. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.